Stock Events

Stock Events

Inhibrx Biosciences 

$66.85
0
+$0+0% Monday 00:14

Statistics

Day High
66.85
Day Low
66.85
52W High
-
52W Low
-
Volume
9
Avg. Volume
-
Mkt Cap
972.27M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

20MayExpected
Q3 2025
Q4 2025
Next
-2.28
-1.92
-1.56
-1.2
Expected EPS
-1.2
Actual EPS
N/A

Financials

843,786%Profit Margin
Profitable
2022
2023
2024
400,000Revenue
3.38BNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow INBX.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals competes in the biotechnology field focusing on immunology and oncology, similar to Inhibrx's focus areas.
AMGEN
AMGN
Mkt Cap160.66B
Amgen operates in the same biopharmaceutical sector, developing therapies in areas like oncology, which overlaps with Inhibrx's pipeline.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences is involved in the discovery, development, and commercialization of innovative therapeutics in areas including oncology, directly competing with Inhibrx.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb offers a range of cancer treatments, competing in the oncology space with Inhibrx.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. is a global healthcare company that produces cancer drugs and vaccines, making it a competitor in the oncology field.
Pfizer
PFE
Mkt Cap140.15B
Pfizer is a large pharmaceutical company with a broad portfolio that includes oncology and immunology drugs, competing with Inhibrx.
Novartis
NVS
Mkt Cap237.61B
Novartis AG focuses on patented medicines for a range of diseases, including cancer, directly competing with Inhibrx's research and development in oncology.
Roche
RHHBY
Mkt Cap258.9B
Roche Holding AG specializes in biotechnology products for oncology, among other areas, making it a competitor in the same field as Inhibrx.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca PLC operates in various therapeutic areas, including oncology, competing with Inhibrx in the development of cancer treatments.

About

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.
Show more...
CEO
ISIN
US45720N1037

Listings

XNAS
US
INBX
BOATS
BOATS
INBX.BOATS

0 Comments

Share your thoughts

FAQ

What is Inhibrx Biosciences stock price today?▼
The current price of INBX.BOATS is $66.85 USD — it has increased by +0% in the past 24 hours. Watch Inhibrx Biosciences stock price performance more closely on the chart.
What is Inhibrx Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Inhibrx Biosciences stocks are traded under the ticker INBX.BOATS.
What is Inhibrx Biosciences market cap?▼
Today Inhibrx Biosciences has the market capitalization of 972.27M
When is the next Inhibrx Biosciences earnings date?▼
Inhibrx Biosciences is going to release the next earnings report on May 20, 2026.
What were Inhibrx Biosciences earnings last quarter?▼
INBX.BOATS earnings for the last quarter are -2.11 USD per share, whereas the estimation was -2.08 USD resulting in a -1.44% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Inhibrx Biosciences revenue for the last year?▼
Inhibrx Biosciences revenue for the last year amounts to 400,000 USD.
What is Inhibrx Biosciences net income for the last year?▼
INBX.BOATS net income for the last year is 3.38B USD.
When did Inhibrx Biosciences complete a stock split?▼
Inhibrx Biosciences has not had any recent stock splits.